Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women, AP said. Both groups saw health improvements in blood pressure, blood sugar and blood fat levels, too.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

The first head-to-head trial of two blockbuster weight-loss drugs has shown Mounjaro is more effective than rival Wegovy. Both drugs led to substantial weight loss, but Mounjaro's 20% weight reduction, after 72 weeks of treatment, exceeded the 14% from Wegovy, according to the trial's findings.